New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
More than 10,000 scientific publications containing EUDRAGIT
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
These digital avenues have not only revolutionized patient care but also opened up new opportunities for HCPs to build thought leadership in their respective fields
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
Subscribe To Our Newsletter & Stay Updated
